Inovio Ends Enrollment In Anal Dysplasia Study On VGX-3100
Zacks Investment Research | Aug 20, 2019 05:14AM ET
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced that it has completed enrollment in a phase II study evaluating its lead HPV immunotherapy — VGX-3100 — for the treatment of anal dysplasia caused by human papillomavirus (HPV). The study will assess the efficacy and safety of VGX-3100 in 24 adult men and women with anal high-grade squamous intraepithelial lesions (anal HSIL). Preliminary efficacy data from the study is expected to be announced later this year.
Anal HSIL can often lead to HPV-associated squamous cell carcinoma of the anus (SCCA).
Notably, surgical excision, electro-cautery or laser therapy are the only forms of treatment available for patients with HPV-related anal dysplasia. However, half of these patients experience recurrence of the disease within one year of treatment and approximately 70% within three years of treatment, thereby requiring multiple treatment and repeated surgeries.
If approved, Inovio will be able to address this unmet medical need, which could effectively eliminate or delay surgery for the given patient population.
Shares of Inovio were up 2.5% following this news on Monday. However, the stock has plunged 39.3% so far this year wider than the industry’s decline of 2.1%.
VGX-3100, an HPV immunotherapy, is the most advanced candidate in Inovio’s pipeline.
Last month, the company concluded enrollment in another phase II study on VGX-3100 for the treatment of vulvar dysplasia caused by HPV. Interim data from this study is also expected before the end of 2019.
Moreover, in June, Inovio completed enrolling patients in the pivotal phase III study REVEAL 1, which is currently evaluating VGX-3100 for the treatment of cervical dysplasia caused by HPV. In March this year, Inovio had started recruiting patients in the confirmatory REVEAL 2 study. Based on the outcomes from this REVEAL 2 analysis, Inovio plans to submit a regulatory filing, seeking approval for VGX-3100 in 2021.
We would like to remind investors that in July, Inovio announced a strategic restructuring to prioritize the development of its late-stage HPV assets and reallocate capital to develop the fast-to-market product candidates. Following this, the company reduced its annual burn rate by 25% and cut workforce by 28%. Inovio also decided to trim some early-stage R&D programs while terminating the phase I/II study evaluating INO-5401 for the treatment of advanced bladder cancer.
Get The News You Want
Notably, in April this year, Inovio closed patient enrollment in the phase I/II study on its immuno-oncology combo of INO-5401 plus INO-9012 in combination with Regeneron (NASDAQ:REGN) / Sanofi’s (NASDAQ:SNY) PD-1 inhibitor Libtayo (cemiplimab) for treating the newly-diagnosed patients with glioblastoma (GBM).
The company expects to provide the interim progression-free survival and safety data on the above study by this year-end and the overall survival data in 2020.
Zacks Rank & Key Pick
Inovio currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the healthcare sector is Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) , which has a Zacks Rank #2 (Buy). You can see .
Alexion’s earnings estimates have been revised 4.2% upward for 2019 and 2.1% for 2020 over the past 60 days. The stock has rallied 15.8% year to date.
Legalizing THIS Could Be Even Bigger than Marijuana
Americans spend an estimated $150 billion in this industry every year… more than twice as much as they spend on marijuana.
Now that 8 states have fully-legalized it (with several more states following close behind), Zacks has identified 5 stocks that could soar in response to the powerful demand. One industry insider described the future as “mind-blowing” – and early investors can still get in ahead of the surge.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.